Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Phenazine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLA known ✓ | P06280 | 3/20 | 0.59 |
| ▸ | GAA known ✓ | P10253 | 3/20 | 0.59 |
| ▸ | ACHE known ✓ | P22303 | 2/20 | 0.59 |
| ▸ | CACNA1B known ✓ | Q00975 | 1/20 | 0.58 |
| ▸ | MAOA known ✓ | P21397 | 2/20 | 0.50 |
| ▸ | CHRM2 known ✓ | P08172 | 1/20 | 0.50 |
| ▸ | ADRA2A known ✓ | P08913 | 1/20 | 0.50 |
| ▸ | CHRM1 known ✓ | P11229 | 1/20 | 0.50 |
| ▸ | DRD1 known ✓ | P21728 | 1/20 | 0.50 |
| ▸ | SLC6A2 known ✓ | P23975 | 1/20 | 0.50 |
| ▸ | ADRA1A known ✓ | P35348 | 1/20 | 0.50 |
| ▸ | OPRM1 known ✓ | P35372 | 1/20 | 0.50 |
| ▸ | KCNH2 known ✓ | Q12809 | 1/20 | 0.50 |
| ▸ | MAOB known ✓ | P27338 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 7/20 | 0.92 |
| ▸ | NQO2 | P16083 | 6/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.59 |
| ▸ | HPGD | P15428 | 4/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.59 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Phenazine SCHEMBL29356959 | 0.96 | MAPT (1.00) | MAPTNQO2ALDH1A1HPGDKDM4E | |
| Phenazine SCHEMBL9049 | 0.96 | MAPT (1.00) | MAPTNQO2ALDH1A1HPGDKDM4E | |
| Phenazine SCHEMBL27643128 | 0.96 | MAPT (1.00) | MAPTNQO2ALDH1A1HPGDKDM4E | |
| Phenazine SCHEMBL11126178 | 0.92 | MAPT (0.92) | MAPTNQO2ALDH1A1HPGDKDM4E | |
| Phenazine SCHEMBL20475337 | 0.92 | MAPT (0.92) | MAPTNQO2ALDH1A1HPGDKDM4E | |
| Phenazine SCHEMBL17187692 | 0.92 | MAPT (0.92) | MAPTNQO2ALDH1A1HPGDKDM4E | |
| Phenazine SCHEMBL22345160 | 0.92 | MAPT (0.92) | MAPTNQO2ALDH1A1HPGDKDM4E | |
| Phenazine SCHEMBL20475326 | 0.92 | MAPT (0.92) | MAPTNQO2ALDH1A1HPGDKDM4E | |
| Phenazine SCHEMBL10866237 | 0.92 | MAPT (0.92) | MAPTNQO2ALDH1A1HPGDKDM4E | |
| Phenazine SCHEMBL3119916 | 0.92 | MAPT (0.92) | MAPTNQO2ALDH1A1HPGDKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117652038-A | Electrode assembly, secondary battery, battery module, battery pack, and power consumption device | 宁德时代新能源科技股份有限公司 | 2024-03-05 | — | — | CN | claimed |
| CN-116982170-A | Negative electrode plate, secondary battery, battery module, battery pack and power utilization device | 宁德时代新能源科技股份有限公司 | 2023-10-31 | — | — | CN | claimed |
| CN-112004520-B | Modified release pharmaceutical powder compositions comprising a gastric raft formation system with triggered pulsatile drug release | 特瑞斯制药公司 | 2024-08-23 | — | — | CN | disclosed |
| CN-117652038-A | Electrode assembly, secondary battery, battery module, battery pack, and power consumption device | 宁德时代新能源科技股份有限公司 | 2024-03-05 | — | — | CN | disclosed |
| CN-116982170-A | Negative electrode plate, secondary battery, battery module, battery pack and power utilization device | 宁德时代新能源科技股份有限公司 | 2023-10-31 | — | — | CN | disclosed |
| CN-116507327-A | Chewable formulations | 礼蓝动物保健有限公司 | 2023-07-28 | — | — | CN | disclosed |
| CN-114225045-A | Treatment of tumors caused by metabolic dysfunction | 辛德弗雷克斯公司 | 2022-03-25 | — | — | CN | disclosed |
| CN-108697807-B | Treatment of tumors caused by metabolic dysfunction | 辛德弗雷克斯公司 | 2021-11-26 | — | — | CN | disclosed |
| CN-111818954-B | Breath actuated inhaler | 诺尔顿沃特福德有限公司 | 2021-11-05 | — | — | CN | disclosed |
| CN-112979681-B | Sulfur-containing compound with nerve rehabilitation effect and application thereof | 深圳市第二人民医院(深圳市转化医学研究院) | 2021-08-10 | — | — | CN | disclosed |
| CN-112979663-B | Nitrogen-containing compound with nerve rehabilitation effect and application thereof | 深圳市第二人民医院(深圳市转化医学研究院) | 2021-08-10 | — | — | CN | disclosed |
| CN-102325550-B | Photodynamic therapy and anti-vegf agent use in conjunction in the choroidal neovascular system that treatment is harmful | QLT公司 | 2016-10-26 | — | — | CN | disclosed |
| US-20140261517-A1 | COMPOSITIONS AND METHODS FOR TREATING KERATIN BASED FIBERS | COOLWAY INC. (US) | 2014-09-18 | — | — | US | disclosed |
| US-8444716-B1 | Soluble solid hair coloring article | THE PROCTER & GAMBLE COMPANY (US) | 2013-05-21 | — | — | US | disclosed |
| US-20120297556-A1 | SOLUBLE SOLID HAIR COLORING ARTICLE | THE PROCTER & GAMBLE COMPANY | 2012-11-29 | — | — | US | disclosed |
| CN-1964692-A | Cationic quinoxaline thiazole azo dye-containing colorants | WELLA AG (DE) | 2007-05-16 | — | — | CN | disclosed |
| US-20050257328-A1 | Agent for simultaneously dying and bringhtening keratin fibers | WELLA AKTIENGESELLSCHAFT (DE) | 2005-11-24 | — | — | US | disclosed |
| CN-1201399-A | method and apparatus for destroying chemical warfare agents | COMMODORE APPLIED TECHNOLOGIES (US) | 1998-12-09 | — | — | CN | disclosed |
| EP-0725623-A1 | COSMETIC COMPOSITION COMPRISING A HYDROCALCHONE AND OPTIONALLY RETINOL OR A DERIVATIVE THEREOF | UNILEVER PLC (GB) | 1996-08-14 | — | — | EP | disclosed |
| WO-1995011662-A1 | COSMETIC COMPOSITION COMPRISING A HYDROCALCHONE AND OPTIONALLY RETINOL OR A DERIVATIVE THEREOF | UNILEVER PLC (GB) | 1995-05-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120297556-A1 | SOLUBLE SOLID HAIR COLORING ARTICLE | CUTA, SUCLG1, SHH | GLA 2280/4885GAA 4542/4885ACHE 4417/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.